Latest News

UHN Start-up AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases

February 01, 2018 /in Latest News


Company to initiate Phase 2 trial with lead gene therapy, AVR‑RD‑01, based on promising initial clinical data in Fabry disease

Strong investor syndicate supports multi-product portfolio with three additional gene therapies for Gaucher disease, cystinosis and Pompe disease

Cambridge, MA, February 1, 2018AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, announced today that it has completed a $60 million Series B financing.  Proceeds from the financing will be used to advance multiple gene therapies from...

Read More

UHN Start-up BlueRock Named Finalist in 7th Annual Canadian Innovation Awards

January 15, 2018 /in Latest News

The Canadian Innovation Awards celebrate the best and brightest in the Canadian technology community. Now in its seventh year, the awards acknowledge outstanding startups, innovative businesses and influential individuals. After pouring over thousands of nominations, the finalists for this year's Canadian Innovation Awards have been named including UHN start-up BlueRock Therapeutics under this year's Health and Therapeutics category!

Learn more and cast your vote until February 2 at!

UHN Start-up BlueRock Named #1 inTop 20 Life Science Startups to Watch in 2018 by BioSpace

January 15, 2018 /in Latest News

NextGen Bio Class of 2018

BioSpace has revealed its NextGen Bio “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015, and UHN start-up ...

Read More

Join us with UHN’s Mark Taylor and Rotman’s Will Mitchell on "Overview of the MedTech Sector" on Jan. 24!

January 15, 2018 /in Latest News

Presented by the Rotman Centre for Health Sector Strategy in partnership with the University Health Network Office of Technology Development & Commercialization, this session is one in a series whose goal is to address the key strategic trends to aid those working within the industry as well as entrepreneurs or new entrants to the medical devices arena. Topics and examples will focus on Canadian and global companies. Participation will involve focused pre-readings, together with active engagement in discussions during the sessions.


  • Prof. Will Mitchell, Anthony S. Fell Chair in New Technologies and Commercialization; Professor of Strategic Management, Rotman School of Managment, University of Toronto; and

  • ...

Read More

UHN Start-up NanoVista Profiled in Scientific American as One of Ten Start-ups Changing Healthcare!

December 21, 2017 /in Latest News

UHN start-up Nanovista, specializing in visualization agents designed specifically to enhance the performance of image-guided interventions such as surgery, radiotherapy and drug delivery, was named amongst Scientific American's Top Ten Start-ups Changing Healthcare. Learn more about the exciting advances in enhancing the accuracy of surgical resection NanoVista is making here

2 UHN Start-ups Named in Top Cell & Gene Therapy Biotechs to Watch In 2018

December 15, 2017 /in Latest News

Congratulations to UHN start-ups AVROBIO and BlueRock Therapeutics for being recognized as two of the top five biotechs to watch in 2018 by Phacilitate!

Read details here



Video recording now available: TDC's Panel on Diagnostics & Prognostics: Journey to Patient Impact

November 24, 2017 /in Latest News

On November 21st, UHN's Technology Development & Commercialization invited the UHN Community to join anexciting panel of experts in the diagnostics/prognostics area as they discussed the challenges to and strategies for getting these tests into the market.  We were privileged to have panelsts from LifeLabsDynacareGeneseeq Technology, and Bereskin & Parr present to discuss the pathway to developing diagnostics/prognostics towards patient impact.  The session was recorded for those that were unable to attend and can be viewed in its entirety here

Princess Margaret's Ultimate Transformer

November 28, 2017 /in Latest News

Progress in nanotechnology is opening a realm of possibilities for Dr. Gang Zheng, Senior Scientist, and his team at The Princess Margaret. This innovative approach could offer real-time feedback in cancer diagnosis and treatment.

Nanoparticles are small enough to reach almost any part of the body, giving them remarkable potential.

Biological processes happen at the nanoscale. Cancer is no exception. With imaging done via nanoparticles, cancer can be detected in its earliest stages, when just a few cells are affected. These same nanoparticles can also be directed to embed themselves in tumours, deliver targeted treatments, and offer...

Read More

Liquid Biopsy Innovations at UHN

November 28, 2017 /in Latest News

What if your blood could predict your response to cancer treatment? Dr. Suzanne Kamel-Reid, Head, Laboratory Genetics, UHN, has been exploring how that question applies to lung cancer patients since 2016. The results of her study, co-led by Dr. Ming-Sound Tsao, Senior Scientist, and Dr. Tracy Stockley, Associate Director, Laboratory Genetics with The Princess Margaret, used blood to predict the presence of a mutation in tissue to optimize treatment.

“We’ve been able to optimize and validate a simple blood test, and now implement it clinically. We believe we are the first lab in Canada to offer this to our patients,” says Dr. Kamel-Reid.

Samples were studied at laboratories across the country, including Ontario, British Columbia,...

Read More

TDC launches new website!

November 24, 2017 /in Latest News

TDC is pleased to announce the launch of a new website! We have added enhanced content tailored to provide the most useful resource possible to both our internal UHN community, as well as the external industry and investor communities. For instance, we've now provided an up-to-date searchable listing of all of UHN's currently availble technologies, information on working successfully with TDC and UHN, frequently asked questions, and  access to various document templates even when off the UHN network, in addition to other useful content. 

We will be releasing additional helpful resources on commercialization at UHN in the coming months as well.  We welcome you to peruse our new website for this and other new and...

Read More

UHN Named Canada’s Top Research Hospital

November 09, 2017 /in Latest News

UHN named the top-funded research hospital in Canada by RE$EARCH Infosource Inc.

Announced on Nov 9, 2017

UHN was ranked number one on the 2017 list of Canada’s Top 40 Research Hospitals, released by RE$EARCH Infosource Inc.

The annual rankings compare research hospitals across Canada according to their research funding data. Funds that were considered included grants, contributions and contracts from all internal and external government and non-government sources.

UHN research expenditures totaled $332 million in the 2016 fiscal year, a value that earned the UHN the top rank for the seventh year in a row. In comparison to last year, UHN research expenditure funding increased by...

Read More

UHN Start-up Thornhill Medical Wins Second Place in International Marine Innovation and Entrepreneurship Competition in China

November 07, 2017 /in Latest News

BEIJING, Qingdao, November 6, 2017 

International Marine Innovation and Entrepreneurship Competition (MTEC) Finals held in Qingdao Blue Valley on the 6th. After the selection of 10 preliminary matches in 6 countries, a total of 50 teams entered the finals. Eventually, the Eco-Friendly Marine Coatings team from Germany won the championship and received 500,000 RMB bonuses and the start-up counseling and support services provided by Shandong University.  The team from Thornhill Medical (an innovative medical device company) from Toronto Canada was the runner up in second place and recieved 300,000 RMB bonuses and start-up counseling and support services as well. 

2017 International Marine Innovation and Entrepreneurship Competition (MTEC) is by far one of the largest marine international innovation and entrepreneurship competitions in the world. It is co-founded and...

Read More

The Jenex Corporation, in Collaboration with UHN’s Techna Institute, Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)

October 16, 2017 /in Latest News

Toronto, Ontario--(Newsfile Corp. - October 12, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap.

Dr. Alyson Kelvin at UHN reported the following:

"To evaluate the effectiveness of the Jenex TherOZap device against the infectivity of Zika virus, cells were infected with a range of Zika virus doses and treated with the Jenex device with heat. In the cells...

Read More

UHN Start-up AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis

October 10, 2017 /in Latest News
Cystinosis Program Becomes Company’s Fourth Gene Therapy  for Lysosomal Storage Disorders

Cambridge, MA, October 4, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to cystinosis. This program becomes AVROBIO’s fourth gene therapy for lysosomal storage disorders (LSDs), and with an anticipated IND filing later this year is expected to enter the clinic in early 2018. The cystinosis program was licensed from GenStem Therapeutics, Inc. Terms of the license agreement were not disclosed.

“This cystinosis program is a strong strategic fit with our pipeline,” said Geoff MacKay, AVROBIO’s President and Chief Executive Officer. “We are pleased to...

Read More

Bauer Launches Innovative NeuroShield in Canada, Co-Invented by the Founder of UHN Spin-off Thornhill Medical

September 26, 2017 /in Latest News



TORONTO, September 26, 2017 (  Bauer, the world's leading manufacturer of ice hockey equipment, recently launched the first athletic product clinically shown to help protect the brain from the inside during sports-related impacts. Continuing Bauer Hockey's rich history of delivering game-changing technologies, the BAUER NeuroShield collar revolutionizes head protection with an innovative approach that delivers peer-reviewed scientific benefits.

The technology behind NeuroShield was discovered by Dr. David Smith, who was inspired by the woodpecker's ability to...

Read More

UHN Start-up AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease

September 21, 2017 /in Latest News

Pre-Clinical Program Becomes Company’s Third GeneTherapy
for Lysosomal Storage Disorders

Pre-Clinical Proof-of-Concept Demonstrated

Cambridge, MA, September 20, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO’s third gene therapy for Lysosomal Storage Disorders (LSDs), following on the heels of the Company’s Phase 1 Fabry program and pre-Phase 1/2 Gaucher program. AVROBIO’s gene therapy for Pompe disease utilizes a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes.

“Pompe disease is a serious lysosomal storage disorder with significant unmet need; our gene therapy is...

Read More

UHN Start-up MyndTec Announces 510(k) Clearance for MyndMove® Therapy for Individuals with Upper Extremity Paralysis

September 18, 2017 /in Latest News

MISSISSAUGA, ON, Sept. 8, 2017 /CNW/ - MyndTec, an award-winning Canadian medical technology company announced today it has received 510(k) clearance to market its landmark product MyndMove®.  MyndTec is a pioneer in the treatment of arm and hand paralysis caused by stroke or spinal cord injury.

"This is a major milestone in the evolution of our company," said MyndTec Founder Dr. Milos R. Popovic.  "We are delighted that we can now offer this life-changing therapy to patients in the U.S. with upper extremity paralysis."

MyndTec intends to initiate a pilot launch of MyndMove® into the U.S. market which complements a product introduction already underway in Canada with a previously announced approval from Health Canada.

MyndMove® Therapy is a functional electric stimulation (FES) based...

Read More

UHN’s Techna Institute, in Collaboration with Jenex, to release initial results on Zika virus deactivation testing

September 14, 2017 /in Latest News


For Immediate Release


Jenex Reports Expected Date of Test Results for TherOZap™ at Inactivating the Zika Virus

Toronto, Ontario – (September 14, 2017) The Jenex Corporation (“Jenex”, or the “Company”, NEX: JEN.H), a progressive medical device technology company, would like to report that the Techna Institute at UHN has informed Jenex that the initial data results for TherOZap at inactivating the Zika virus are expected to be received during the week of October 2nd with an outside reporting date during the second week of October.  Techna Institute has informed Jenex that additional time may be required outside of the first week of October if necessary to provide the data.  Jenex expects to report additional...

Read More

We’re hiring: Commercialization Intern (8 months full-time, Oct-May)

September 13, 2017 /in Latest News


Are you a graduated student with an interest in commercialization? Experience with market analysis? A scientific background? Join the TDC team as our TDC Commercialization Intern starting this Fall, 2017.

Please note this opportunity is not available to current students.

Job Title:  Commercialization Intern (8 months full-time, Oct-May)
Company Name:  University Health Network, Office of Technology Development & Commercialization
Location:   MaRS Discovery District, 101...
Read More

Tribute to Dr. Michael Sharpe, UHN Researcher, for Contribution to the Advancement of Radiation Therapy

August 31, 2017 /in Latest News

TDC is proud to have helped enable an important advance in radiation therapy and radiation therapy training, and to honor the memory of one of our great inventors, Dr. Michael Sharpe.

In this video, UHN outlines the impact of the automatic treatment planning innovations it recently licensed to RaySearch, enabling algorithms from Princess Margaret Cancer Center to be integrated into RayStation.